ENOV Stock Analysis: Enovis | NYSE
Medical Devices | NYSE, USA | Market Cap: 1.424m USD | 12M Return: -13.2% | US1940145022 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 30.4M
EPS Trend: 95.5%
Qual. Beats: 0
Rev. Trend: 95.8%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Enovis Corporation (NYSE: ENOV) is a U.S.-based medical technology company founded in 1995 and headquartered in Wilmington, Delaware. The company, formerly known as Colfax Corporation, operates through two main segments: Prevention and Recovery, which provides orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems, compression garments, electrical stimulators for pain management, and physical therapy products; and Reconstructive, which develops and markets surgical implants, instrumentation, and enabling technologies used in joint replacement, limb reconstruction, and foot, ankle, and extremity procedures.
The company sells to a broad range of healthcare professionals, including orthopedic specialists, surgeons, primary care physicians, physical therapists, podiatrists, chiropractors, and athletic trainers, and distributes its products through independent distributors, direct sales channels, and directly to patients. Enovis operates within the global orthopedic medical device sector, an industry supported by aging populations, rising rates of musculoskeletal conditions, and growing demand for joint replacement and rehabilitation products.
- Reconstructive segment drives growth via hip and knee implant demand
- Prevention and Recovery braces and pain management sales expand steadily
- Margin expansion from operational efficiency and portfolio reshaping efforts
| Net Income: -1.10b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA 1.77 > 1.0 |
| NWC/Revenue: 26.24% < 20% (prev 32.53%; Δ -6.28% < -1%) |
| CFO/TA 0.07 > 3% & CFO 270.1m > Net Income -1.10b |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.98 > 1.5 & < 3 |
| Outstanding Shares: last quarter (57.6m) vs 12m ago 1.42% < -2% |
| Gross Margin: 57.43% > 18% (prev 57.59%; Δ -0.16% > 0.5%) |
| Asset Turnover: 52.27% > 50% (prev 43.60%; Δ 8.66% > 0%) |
| Interest Coverage Ratio: -18.23 > 6 (EBIT TTM -1.01b / Interest Expense TTM 55.5m) |
| A: 0.16 (Total Current Assets 1.21b - Total Current Liabilities 612.1m) / Total Assets 3.77b |
| B: -0.39 (Retained Earnings -1.48b / Total Assets 3.77b) |
| C: -0.23 (EBIT TTM -1.01b / Avg Total Assets 4.39b) |
| D: 0.65 (Book Value of Equity 1.48b / Total Liabilities 2.29b) |
| Altman-Z'' = -1.10 = CCC |
| DSRI: 0.93 (Receivables 441.8m/453.7m, Revenue 2.30b/2.19b) |
| GMI: 1.00 (GM 57.59% / 57.43%) |
| AQI: 0.81 (AQ_t 0.52 / AQ_t-1 0.64) |
| SGI: 1.05 (Revenue 2.30b / 2.19b) |
| TATA: -0.36 (NI -1.10b - CFO 270.1m) / TA 3.77b) |
| Beneish M = -3.20 (Cap -4..+1) = AA |
As of August 19, 2026, the stock is trading at USD 25.64 with a total of 658,665 shares traded. Over the past week, the price has changed by +4.23%, over one month by -4.47%, over three months by +1.54% and over the past year by -13.23%.
Current recommended Stop Loss: 22.40 (which is 12.6% or 2 ATR below the current price).
Enovis has received a consensus analysts rating of 4.55. Therefore, it is recommended to buy ENOV.
- StrongBuy: 7
- Buy: 3
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 41.3 | 60.9% |
P/E Forward = 6.5703
P/S = 0.62
P/B = 0.9464
P/EG = 1.8989
Revenue TTM = 2.30b USD
EBIT TTM = -1.01b USD
EBITDA TTM = -716.9m USD
Long Term Debt = 1.25b USD (from longTermDebt, last quarter)
Short Term Debt = 62.8m USD (from shortTermDebt, last quarter)
Debt = 1.45b USD (from shortLongTermDebtTotal, last quarter) + Leases 84.5m
Net Debt = 1.44b USD (calculated: Debt 1.45b - CCE 12.6m)
Enterprise Value = 2.86b USD (1.42b + Debt 1.45b - CCE 12.6m)
Interest Coverage Ratio = -18.23 (Ebit TTM -1.01b / Interest Expense TTM 55.5m)
EV/FCF = 45.00x (Enterprise Value 2.86b / FCF TTM 63.7m)
FCF Yield = 2.22% (FCF TTM 63.7m / Enterprise Value 2.86b)
FCF Margin = 2.77% (FCF TTM 63.7m / Revenue TTM 2.30b)
Net Margin = -47.97% (Net Income TTM -1.10b / Revenue TTM 2.30b)
Gross Margin = 57.43% ((Revenue TTM 2.30b - Cost of Revenue TTM 977.6m) / Revenue TTM)
Gross Margin QoQ = 61.64% (prev 54.92%)
Tobins Q-Ratio = 0.76 (Enterprise Value 2.86b / Total Assets 3.77b)
Interest Expense / Debt = 3.82% (Interest Expense 55.5m / Debt 1.45b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -800.1m (EBIT -1.01b * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.98 (Total Current Assets 1.21b / Total Current Liabilities 612.1m)
Debt / Equity = 0.98 (Debt 1.45b / totalStockholderEquity, last quarter 1.48b)
Debt / EBITDA = -2.01 (negative EBITDA) (Net Debt 1.44b / EBITDA -716.9m)
Debt / FCF = 22.64 (Net Debt 1.44b / FCF TTM 63.7m)
Total Stockholder Equity = 1.62b (last 4 quarters mean from totalStockholderEquity)
RoA = -25.07% (Net Income -1.10b / Total Assets 3.77b)
RoE = -68.17% (Net Income TTM -1.10b / Total Stockholder Equity 1.62b)
RoCE = -35.37% (EBIT -1.01b / Capital Employed (Equity 1.62b + L.T.Debt 1.25b))
RoIC = -24.97% (negative operating profit) (NOPAT -800.1m / Invested Capital 3.20b)
WACC = 6.30% (E(1.42b)/V(2.88b) * Re(9.65%) + D(1.45b)/V(2.88b) * Rd(3.82%) * (1-Tc(0.21)))
Discount Rate = 9.65% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 65.16 | Cagr: 2.33%
[DCF] Terminal Value 75.44% ; FCFF base≈63.7m ; Y1≈63.9m ; Y5≈67.7m
[DCF] Fair Price = N/A (negative equity: EV 1.05b - Net Debt 1.44b = -387.9m; debt exceeds intrinsic value)
EPS Correlation: 95.52 | EPS CAGR: 17.30% | SUE: -0.82 | # QB: 0
Revenue Correlation: 95.83 | Revenue CAGR: 12.96% | SUE: 0.13 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.79 | Chg30d=-6.56% | Revisions=-8% | Analysts=13
EPS current Year (2026-12-31): EPS=3.64 | Chg30d=-0.33% | Revisions=+31% | GrowthEPS=+10.2% | GrowthRev=+4.2%
EPS next Year (2027-12-31): EPS=4.06 | Chg30d=-0.58% | Revisions=+25% | GrowthEPS=+11.5% | GrowthRev=+5.0%
[Analyst] Revisions Ratio: +17% (up=12, down=8)